ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia

Over the past decades, there has been a significant expansion of the treatment options for patients with chronic lymphocytic leukemia (CLL) due to Brutons tyrosine kinase (BTK) inhibitors, which changed approaches in CLL therapy. Ibrutinib was the first BTK inhibitor approved for CLL treatment, but...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tatiana E. Bialik, Vladimir I. Vorob'ev, Valerii A. Ionin, Loic Ysebaert, Kamil D. Kaplanov, Larisa P. Mendeleeva, Evgenii A. Nikitin, Vadim V. Ptushkin, Olga S. Samoilova, Elena A. Stadnik
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	chronic lymphocytic leukemia bruton’s tyrosine kinase inhibitors target therapy acalabrutinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1c92f70a6bda4d418cdf39c54aceadf2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1c92f70a6bda4d418cdf39c54aceadf2
record_format	dspace
spelling	oai:doaj.org-article:1c92f70a6bda4d418cdf39c54aceadf22021-11-30T16:55:01ZELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia1815-14341815-144210.26442/18151434.2021.3.201207https://doaj.org/article/1c92f70a6bda4d418cdf39c54aceadf22021-11-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/88010/pdfhttps://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Over the past decades, there has been a significant expansion of the treatment options for patients with chronic lymphocytic leukemia (CLL) due to Brutons tyrosine kinase (BTK) inhibitors, which changed approaches in CLL therapy. Ibrutinib was the first BTK inhibitor approved for CLL treatment, but adverse events such as atrial fibrillation and hypertension may limit the use of ibrutinib. In the first head-to-head trial of acalabrutinib and ibrutinib ELEVATE-RR, acalabrutinib was statistically superior to ibrutinib in all-grade atrial fibrillation/flutter (9.4% vs 16.0%; р=0.023). In all-grade arterial hypertension (9.4% vs 23.2%) and grade 3 (4.1% vs 9.1%) acalabrutinib was statistically superior to ibrutinib. Acalabrutinib demonstrated fewer discontinuations due to adverse events (14.7%) vs ibrutinib (21.3%). Based on ELEVATE-RR results acalabrutinib should be considered as a drug of choice among BTK inhibitors for CLL patients, including patients with cardiovascular diseases and risks of cardiovascular diseases.Tatiana E. BialikVladimir I. Vorob'evValerii A. IoninLoic YsebaertKamil D. KaplanovLarisa P. MendeleevaEvgenii A. NikitinVadim V. PtushkinOlga S. SamoilovaElena A. StadnikIP Habib O.N.articlechronic lymphocytic leukemiabruton’s tyrosine kinase inhibitorstarget therapyacalabrutinibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 3, Pp 404-406 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	chronic lymphocytic leukemia bruton’s tyrosine kinase inhibitors target therapy acalabrutinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	chronic lymphocytic leukemia bruton’s tyrosine kinase inhibitors target therapy acalabrutinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Tatiana E. Bialik Vladimir I. Vorob'ev Valerii A. Ionin Loic Ysebaert Kamil D. Kaplanov Larisa P. Mendeleeva Evgenii A. Nikitin Vadim V. Ptushkin Olga S. Samoilova Elena A. Stadnik ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
description	Over the past decades, there has been a significant expansion of the treatment options for patients with chronic lymphocytic leukemia (CLL) due to Brutons tyrosine kinase (BTK) inhibitors, which changed approaches in CLL therapy. Ibrutinib was the first BTK inhibitor approved for CLL treatment, but adverse events such as atrial fibrillation and hypertension may limit the use of ibrutinib. In the first head-to-head trial of acalabrutinib and ibrutinib ELEVATE-RR, acalabrutinib was statistically superior to ibrutinib in all-grade atrial fibrillation/flutter (9.4% vs 16.0%; р=0.023). In all-grade arterial hypertension (9.4% vs 23.2%) and grade 3 (4.1% vs 9.1%) acalabrutinib was statistically superior to ibrutinib. Acalabrutinib demonstrated fewer discontinuations due to adverse events (14.7%) vs ibrutinib (21.3%). Based on ELEVATE-RR results acalabrutinib should be considered as a drug of choice among BTK inhibitors for CLL patients, including patients with cardiovascular diseases and risks of cardiovascular diseases.
format	article
author	Tatiana E. Bialik Vladimir I. Vorob'ev Valerii A. Ionin Loic Ysebaert Kamil D. Kaplanov Larisa P. Mendeleeva Evgenii A. Nikitin Vadim V. Ptushkin Olga S. Samoilova Elena A. Stadnik
author_facet	Tatiana E. Bialik Vladimir I. Vorob'ev Valerii A. Ionin Loic Ysebaert Kamil D. Kaplanov Larisa P. Mendeleeva Evgenii A. Nikitin Vadim V. Ptushkin Olga S. Samoilova Elena A. Stadnik
author_sort	Tatiana E. Bialik
title	ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
title_short	ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
title_full	ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
title_fullStr	ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
title_full_unstemmed	ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
title_sort	elevate-rr – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/1c92f70a6bda4d418cdf39c54aceadf2
work_keys_str_mv	AT tatianaebialik elevaterrfirstheadtoheadtrialofacalabrutinibversusibrutinibinpreviouslytreatedhighriskchroniclymphocyticleukemia AT vladimirivorobev elevaterrfirstheadtoheadtrialofacalabrutinibversusibrutinibinpreviouslytreatedhighriskchroniclymphocyticleukemia AT valeriiaionin elevaterrfirstheadtoheadtrialofacalabrutinibversusibrutinibinpreviouslytreatedhighriskchroniclymphocyticleukemia AT loicysebaert elevaterrfirstheadtoheadtrialofacalabrutinibversusibrutinibinpreviouslytreatedhighriskchroniclymphocyticleukemia AT kamildkaplanov elevaterrfirstheadtoheadtrialofacalabrutinibversusibrutinibinpreviouslytreatedhighriskchroniclymphocyticleukemia AT larisapmendeleeva elevaterrfirstheadtoheadtrialofacalabrutinibversusibrutinibinpreviouslytreatedhighriskchroniclymphocyticleukemia AT evgeniianikitin elevaterrfirstheadtoheadtrialofacalabrutinibversusibrutinibinpreviouslytreatedhighriskchroniclymphocyticleukemia AT vadimvptushkin elevaterrfirstheadtoheadtrialofacalabrutinibversusibrutinibinpreviouslytreatedhighriskchroniclymphocyticleukemia AT olgassamoilova elevaterrfirstheadtoheadtrialofacalabrutinibversusibrutinibinpreviouslytreatedhighriskchroniclymphocyticleukemia AT elenaastadnik elevaterrfirstheadtoheadtrialofacalabrutinibversusibrutinibinpreviouslytreatedhighriskchroniclymphocyticleukemia
_version_	1718406432361021440

ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia

Ejemplares similares